Autoantibody Development under Treatment with Immune-Checkpoint Inhibitors
Open accessPublished version of a preprint
The DOI matches its Crossref record; 40 of the 42 references it cites were found in a registry or an index.
Abstract
Immune-checkpoint inhibitors (ICIs) activate the immune system to assault cancer cells in a manner that is not antigen specific. We hypothesized that tolerance may also be broken to autoantigens, resulting in autoantibody formation, which could be associated with immune-related adverse events (irAEs) and antitumor efficacy. Twenty-three common clinical autoantibodies in pre- and posttreatment sera from 133 ipilimumab-treated melanoma patients were determined, and their development linked to the occurrence of irAEs, best overall response, and survival. Autoantibodies developed in 19.2% (19/99) of patients who were autoantibody-negative pretreatment. A nonsignificant association was observed between development of any autoantibodies and any irAEs [OR, 2.92; 95% confidence interval (CI) 0.85-10.01]. Patients with antithyroid antibodies after ipilimumab had significantly more thyroid dysfunction under subsequent anti-PD-1 therapy: 7/11 (54.6%) patients with antithyroid antibodies after ipilimumab developed thyroid dysfunction under anti-PD1 versus 7/49 (14.3%) patients without antibodies (OR, 9.96; 95% CI, 1.94-51.1). Patients who developed autoantibodies showed a trend for better survival (HR for all-cause death: 0.66; 95% CI, 0.34-1.26) and therapy response (OR, 2.64; 95% CI, 0.85-8.16). We conclude that autoantibodies develop under ipilimumab treatment and could be a potential marker of ICI toxicity and efficacy.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Nearly 25% of patients developed new autoantibodies following treatment with ICB for melanoma; however, the typical antibody targets observed in autoimmune disease are not always seen in irAEs even when the same target is affected”
From Hallmarks of response, resistance, and toxicity to immune checkpoint blockade (2021) · cites this paper as de Moel et al., 2019
Citations
Cites
The blockade of immune checkpoints in cancer immunotherapy
Pardoll, D. M. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3239 · Cited by 13,838 · cited 1×
“ICIs inhibit negative costimulatory signals to T cells, thereby enhancing antitumor T-cell responses (2).”
BackgroundROLE OF ABERRANT HLA-DR EXPRESSION AND ANTIGEN PRESENTATION IN INDUCTION OF ENDOCRINE AUTOIMMUNITY
Bottazzo, G., Hanafusa, T., Pujol-Borrell, R., & Feldmann, M. (1983) · The Lancet · doi:10.1016/s0140-6736(83)90629-3 · Cited by 1,256 · cited 1×
“11–17), mutations in CTLA-4 (18, 19), upregulation of MHC class II molecules on thyrocytes leading to thyroid antigen presentation to autoreactive cells (20), or as we show here, ipilimumab treatment.”
BackgroundSafety Profile of Nivolumab Monotherapy: A Pooled Analysis of Patients With Advanced Melanoma
Weber, J. S., Hodi, F. S., Wolchok, J. D., Topalian, S. L., Schadendorf, D., Larkin, J., Sznol, M., Long, G. V., Li, H., Waxman, I. M., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2015.66.1389 · Cited by 1,158 · cited 7×
“Although several studies report an association between irAEs and clinical outcome under ICIs (31, 32), we did not find such an association in this study.”
BackgroundInfluentialBertrand, A., Kostine, M., Barnetche, T., Truchetet, M.-E., & Schaeverbeke, T. (2015) · BMC Medicine · doi:10.1186/s12916-015-0455-8 · Cited by 704 · cited 5×
“Cancer Immunol Res; 7(1) January 2019 Cancer Immunology Research 8”
BackgroundInfluentialOsorio, J. C., Ni, A., Chaft, J. E., Pollina, R., Kasler, M. K., Stephens, D., Rodriguez, C., Cambridge, L., Rizvi, H., Wolchok, J. D., et al. (2017) · Annals of Oncology · doi:10.1093/annonc/mdw640 · Cited by 659 · cited 2×
“A relationship between immune-related thyroid dysfunction and clinical outcome has been described previously for various types of cancer immunotherapy, including IL2 (33–35), interferon-2a (35–37), and pembrolizumab (29).”
BackgroundPrognostic Significance of Autoimmunity during Treatment of Melanoma with Interferon
Gogas, H., Ioannovich, J., Dafni, U., Stavropoulou-Giokas, C., Frangia, K., Tsoutsos, D., Panagiotou, P., Polyzos, A., Papadopoulos, O., Stratigos, A., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa053007 · Cited by 566
Prognostic significance of autoimmunity during treatment of melanoma with interferon
Krauze, M. T., Tarhini, A., Gogas, H., & Kirkwood, J. M. (2011) · Seminars in Immunopathology · doi:10.1007/s00281-011-0247-y · Cited by 507 · cited 1×
“Some of these studies also found a response or survival benefit under IL2 (33, 34) or interferon-2a (36) for patients who Figure 2.”
BackgroundInflammatory arthritis and sicca syndrome induced by nivolumab and ipilimumab
Cappelli, L. C., Gutierrez, A. K., Baer, A. N., Albayda, J., Manno, R. L., Haque, U., Lipson, E. J., Bleich, K. B., Shah, A. A., Naidoo, J., et al. (2017) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2016-209595 · Cited by 400
Chan, E. K. L., Damoiseaux, J., Carballo, O. G., Conrad, K., de Melo Cruvinel, W., Francescantonio, P. L. C., Fritzler, M. J., Garcia-De La Torre, I., Herold, M., Mimori, T., et al. (2015) · Frontiers in Immunology · doi:10.3389/fimmu.2015.00412 · Cited by 383
Anti–CTLA-4 therapy broadens the melanoma-reactive CD8 + T cell response
Kvistborg, P., Philips, D., Kelderman, S., Hageman, L., Ottensmeier, C., Joseph-Pietras, D., Welters, M. J. P., van der Burg, S., Kapiteijn, E., Michielin, O., et al. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3008918 · Cited by 378 · cited 2×
“ICIs execute their function in an antigen-independent manner by diversifying the T-cell repertoire against a multitude of tumor antigens (3, 5).”
BackgroundResultSelf-citation
Cited by
Hallmarks of response, resistance, and toxicity to immune checkpoint blockade
Morad, G., Helmink, B. A., Sharma, P., & Wargo, J. A. (2021) · Cell · doi:10.1016/j.cell.2021.09.020 · Cited by 1,648
Immune-related adverse events of checkpoint inhibitors
Ramos-Casals, M., Brahmer, J. R., Callahan, M. K., Flores-Chávez, A., Keegan, N., Khamashta, M. A., Lambotte, O., Mariette, X., Prat, A., & Suárez-Almazor, M. E. (2020) · Nature Reviews Disease Primers · doi:10.1038/s41572-020-0160-6 · Cited by 1,412
Immune-related adverse events of immune checkpoint inhibitors: a review
Yin, Q., Wu, L., Han, L., Zheng, X., Tong, R., Li, L., Bai, L., & Bian, Y. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1167975 · Cited by 446
“TPOAb and anti-thyroglobulin antibodies (TGAb) were the most common (60).”
BackgroundZhou, X., Yao, Z., Yang, H., Liang, N., Zhang, X., & Zhang, F. (2020) · BMC Medicine · doi:10.1186/s12916-020-01549-2 · Cited by 353
Moving towards personalized treatments of immune-related adverse events
Esfahani, K., Elkrief, A., Calabrese, C., Lapointe, R., Hudson, M., Routy, B., Miller, W. H., & Calabrese, L. (2020) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-020-0352-8 · Cited by 351
Metadata
- Authors
- de Moel, E. C., Rozeman, E. A., Kapiteijn, E. H., Verdegaal, E. M. E., Grummels, A., Bakker, J. A., Huizinga, T. W. J., Haanen, J. B., Toes, R. E. M., & van der Woude, D.
- Affiliations
- 1Department of Rheumatology, Leiden University Medical Center, Leiden, the Netherlands.
- The Netherlands Cancer Institute (NL)
- Leiden University Medical Center (NL)
- ORCID
- Venue
- Cancer Immunology Research
- Published
- 2019-01-01
- Volume
- 7
- Issue
- 1
- Pages
- 6-11
- ISSN
- 2326-6066 (ISSN-L)
- 2326-6074
- OpenAlex
- W2901290947
- Cited by
- 191
- References
- 42
- Citations by year
- 2026: 15 · 2025: 25 · 2024: 33 · 2023: 29 · 2022: 33 · 2021: 26 · 2020: 26 · 2019: 3
- FWCI
- 5.16
- Type
- journal article
- Language
- en
- Open access
- green
- hdl.handle.net
- Locations
- Cancer Immunology Research (publishedVersion)
- PubMed (publishedVersion)
- Leiden Repository (Leiden University) (submittedVersion)
- Data Archiving and Networked Services (DANS) (submittedVersion, other-oa)
- Funders
- Netherlands Organisation for Health Research and Development (91617100)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
- Keywords
- autoantibodies, immune checkpoint inhibitors, ipilimumab, immune-related adverse events, melanoma, thyroid autoantibodies, thyroid dysfunction, anti-PD-1 therapy, self-tolerance, treatment response, survival
- MeSH terms
- Antineoplastic Agents, Immunological, Ipilimumab, Aged, Autoantibodies, Female, Humans, Male, Melanoma, Middle Aged, Skin Neoplasms, Thyroid Gland, Biomarkers, Treatment Outcome, CTLA-4 Antigen
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Autoantibody Development under Treatment with Immune-Checkpoint Inhibitors. https://app.cochat.ai/papers/10.1158/2326-6066.cir-18-0245
- The paper
- de Moel, E. C., Rozeman, E. A., Kapiteijn, E. H., Verdegaal, E. M. E., Grummels, A., Bakker, J. A., Huizinga, T. W. J., Haanen, J. B., Toes, R. E. M., & van der Woude, D. (2019). Autoantibody Development under Treatment with Immune-Checkpoint Inhibitors. Cancer Immunology Research. https://doi.org/10.1158/2326-6066.cir-18-0245
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.